High-dose aldesleukin in renal cell carcinoma: Long-term survival update

Richard I. Fisher, Steven A. Rosenberg, Mario Sznol, David R. Parkinson, Gwendolyn Fyfe

Research output: Contribution to journalArticle

Abstract

PURPOSE: This article updates response duration and survival data for patients with metastatic renal cell carcinoma receiving high-dose recombinant interleukin-2 (rIL-2). PATIENTS AND METHODS: Two hundred fifty-five assessable renal cell carcinoma patients were entered into seven phase II clinical trials. They were administered 600,000 or 720,000 IU/kg rIL-2 by 15- minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximal support. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. All data have been updated as of June 1996 with report forms completed by the clinical investigators. RESULTS: Objective overall responses have now been achieved in 37 of 255 patients (15%) with 17 complete (7%) and 20 partial (8%) responses. Median response duration for all objective responders is 54 months with a range of 3 to 107+ months. Median response duration for all complete responses has not been reached, with a range of 7 to 107+ months. Median response duration for all partial responses is 20 months, with a range of 3 to 97+ months. Median survival for all 255 patients was 16.3 months, and 10% to 20% of patients were estimated to be alive 5 to 10 years following treatment. CONCLUSION: Treatment with high-dose rIL-2 is extremely effective for a subset of patients with metastatic renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)S70-S72
JournalCancer Journal from Scientific American
Volume3
Issue numberSUPPL. 1
StatePublished - Dec 1 1997

    Fingerprint

Keywords

  • Immunotherapy
  • Interleukin-2
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Fyfe, G. (1997). High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer Journal from Scientific American, 3(SUPPL. 1), S70-S72.